Skip to content
The Great News – Lifestyle
Home
Sample Page
Author:
Therini Bio, Inc.
Therini Bio Doses First Patients in Phase 1b Trial of Novel Anti-Inflammatory Therapy, THN391, for Diabetic Macular Edema
May 27, 2026